Astellas Pharma Inc.

ALPMY | OTC

Price Alert Chart Builder DCF Calculator

$16.39

+$0.37 (+2.31%)

At close: Nov 5, 2026, 3:59 PM ET

$16.35

-$0.04 (-0.24%)

After-hours: Nov 5, 2026, 3:59 PM ET

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+2.31%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 5, 2026

72.1

Fundamentals Excellent

Market Sentiment Neutral

Moat Narrow

Sector Rank #44/1024 (Top 4%)

Full Analysis

Key Statistics

Market Data

Market Cap $29.39B

1D Range

16.35 16.84

52W Range

11.32 16.84

Valuation (TTM)

PE 12.15

PB 2.40

EV/EBITDA 7.40

Valuation (NTM)

Forward PE 12.00

Forward PEG 0.38

Price Target $0.00

Cash Flow

FCF Yield 11.9%

SBC Adj. FCF Yield 11.9%

SBC Impact N/A

Margins

Gross Margin 74.7%

Operating Margin 21.8%

FCF Margin 23.8%

Growth (CAGR)

Revenue 3Y | 5Y 14.6% | 12.4%

Dil EPS 3Y | 5Y 51.2% | 30.2%

FCF 3Y | 5Y 27.9% | 13.0%

Returns

ROA 9.9%

ROE 20.4%

ROIC 14.0%

Financial Health

Net Debt

¥345.17B ($2.12B)

Current Ratio 1.20

Interest Coverage 43.91

Dividends

Div Yield 2.81%

Payout Ratio 0.2%

FCF Payout Ratio 25.9%

All Key Statistics

Loading financial charts...

Profile

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide...

Sector Healthcare

Industry Drug Manufacturers - General

Employees 14,099

IPO Date Dec 29, 2009

Website www.astellas.com

Fiscal Year April - March

Full Company Profile

Latest News

1 day ago · zacks.com

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Elevance Health (ELV) have performed compared to their sector so far this year.

17 days ago · zacks.com

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

Here is how Elevance Health (ELV) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

2 months ago · zacks.com

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

3 months ago · zacks.com

New Strong Sell Stocks for August 19th

ASEKY, ALPMY and ATS have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2026.

3 months ago · seekingalpha.com

Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors

The portfolio outperformed the MSCI EAFE benchmark in the second quarter of 2026. Contributors include Infineon Technologies, Tokyo Electron and Recruit Holdings. Detractors include Murata Manufacturing, SoftBank Group and Astellas Pharma.

3 months ago · zacks.com

New Strong Sell Stocks for August 6th

COIN, ALPMY and MUX have been added to the Zacks Rank #5 (Strong Sell) List on August 6th, 2026.

5 months ago · zacks.com

Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

5 months ago · zacks.com

Is Astellas Pharma (ALPMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Earnings

Latest Earnings

Nov 4, 2026

EPS

$0.35

Miss -14.90%

YoY: +16.67%

REV

$3.98B

Beat +4.93%

YoY: +11.82%

Next Earnings

Feb 8, 2027

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞